800-438-8285
770-426-0031 FAX
888-427-9654 CUSTOMER SERVICE
 |
CTSNet
is sponsored in part by an educational grant from |
 |
|
||
CryoValve® SG Pulmonary Human Heart Valve
CRYOLIFE, INC.
|
|
1655 Roberts Boulevard, NW |
|
SynerGraft® Overview
| The Technology | SynerGraft is CryoLife’s patented decellularization technology that serves as the foundation for the next generation of implantable biological tissues. |
| The Process | The SynerGraft process reduces the presence of allogeneic donor cells associated with biological tissues, while maintaining the structural integrity of the biological matrix. |
| The Valve | The CryoValve SG Pulmonary Human Heart Valve is the first allograft heart valve which incorporates the patented technology and undergoes the decellularization process. |
| The Status | The CryoValve SG Pulmonary Human Heart Valve is the first and only human heart valve to receive 510(k) clearance from the US Food and Drug Administration. |
|
|
Percent DNA Reduction in SynerGraft-Processed Heart Valve Tissue Compared to Standard-Processed CryoValve |
Percent Cell Reduction in SynerGraft-Processed Tissue Compared to Standard-Processed CryoValve |
|
|
Pulmonary Myocardium |
>99% |
99% |
|
|
Pulmonary Conduit |
>99% |
99% |
|
|
Pulmonary Leaflet |
>99% |
99% |
PRODUCT FEATURES
- Internal Diameter: 6mm-32mm
- Reduced cell content
- Reduced nucleic acid content
- Reduced cell-associated proteins
- Equivalent strength
- Equivalent hemodynamic function
- Equivalent structural integrity
PRODUCT USES
- Right ventricular outflow reconstructions
- Ross procedure
- Truncus Arteriosus
- Pulmonary Atresia
- Hypoplastic Left Heart Syndrome
- Single Ventricle/Double Outlet